Dianthus Therapeutics, Inc. /DE/ (DNTH) Operating Income (Loss) USD 2017 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Dianthus Therapeutics, Inc. /DE/ quarterly/annual Operating Income (Loss) history and growth rate from 2017 to 2024.
  • Dianthus Therapeutics, Inc. /DE/ Operating Income (Loss) for the quarter ending March 31, 2024 was -$17.8 M, a 132% decline year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ Operating Income (Loss) for the twelve months ending March 31, 2024 was -$58.3 M, a 330% decline year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ annual Operating Income (Loss) for 2023 was -$48.2 M, a 62.2% decline from 2022.
  • Dianthus Therapeutics, Inc. /DE/ annual Operating Income (Loss) for 2022 was -$29.7 M, a 127% decline from 2021.
  • Dianthus Therapeutics, Inc. /DE/ annual Operating Income (Loss) for 2021 was -$13.1 M, a 83.4% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$58.3 M -$17.8 M -$10.2 M -132% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$48.2 M -$17.4 M -$37.8 M -185% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$10.4 M -$15.8 M -$7.51 M -90.9% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$2.85 M -$7.38 M +$10.7 M +59.2% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-03
Q1 2023 -$13.6 M -$7.68 M +$16.2 M +67.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$29.7 M $20.5 M -$21 M -50.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$8.71 M -$8.25 M +$9.99 M +54.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$18.7 M -$18.1 M -$473 K -2.69% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$18.2 M -$23.8 M -$5.14 M -27.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$13.1 M $41.5 M +$60.5 M Oct 1, 2021 Dec 31, 2021 8-K 2023-12-21
Q3 2021 -$73.6 M -$18.2 M +$136 K +0.74% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$73.8 M -$17.6 M +$2.4 M +12% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$76.2 M -$18.7 M +$2.55 M +12% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$78.7 M -$19.1 M +$5.57 M +22.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-08
Q3 2020 -$84.3 M -$18.4 M +$4.26 M +18.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$88.5 M -$20 M -$674 K -3.49% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$87.9 M -$21.2 M -$4.89 M -29.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$83 M -$24.6 M -$6.71 M -37.4% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-03
Q3 2019 -$76.3 M -$22.6 M -$5.94 M -35.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$70.3 M -$19.3 M -$5.31 M -37.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$65 M -$16.4 M -$5.04 M -44.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$60 M -$17.9 M -$9.76 M -119% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-03
Q3 2018 -$50.2 M -$16.7 M -$9.69 M -138% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-03
Q2 2018 -$40.5 M -$14 M +$1.71 M +10.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-03
Q1 2018 -$42.2 M -$11.3 M -$6.5 M -135% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-03
Q4 2017 -$35.7 M -$8.17 M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-19
Q3 2017 -$7.02 M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-19
Q2 2017 -$15.7 M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-19
Q1 2017 -$4.81 M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.